

Table 1 Palliative Prognostic Index

	Partial score
Palliative Performance scale	
10-20	4
30-50	2.5
≥60	0
Oral intake	
Mouthfuls or less	2.5
Reduced, but more than only mouthfuls	1
Normal	0
Edema	
Present	1
Absent	0
Dyspnea at rest	
Present	3.5
Absent	0
Delirium	
Present	4
Absent	0

Table 2 Patient characteristics

	Whole patients	NSCLC	SCLC
Number	84	67	17
Age median (range)	72.5 (45-88)	70 (45-88)	74 (48-79)
Male/Female	74/10	58/9	16/1
PS 1/2/3/4	4/23/40/17	3/18/33/13	1/5/7/4
Histology			
NSCLC			
Adenocarcinoma	35 (41.7%)	35 (52.2%)	0 (0%)
Squamous cell carcinoma	20 (23.8%)	20 (29.9%)	0 (0%)
Others	12 (14.3%)	12 (17.9%)	0 (0%)
SCLC	17 (20.2%)	0 (0%)	17 (100%)
EGFR status			
Wild type	41 (48.8%)	41 (61.2%)	0 (0%)
Mutant	7 (8.3%)	7 (10.5%)	0 (0%)
Unknown	36 (42.9%)	19 (28.4%)	17 (100%)

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung carcinoma; PS, performance status; SCLC, small cell lung carcinoma

Table 3 Risk of overall mortality in patients with lung cancer (Cox proportional hazards model)

		HR	95%CI	P
Gender	Male	1.30	0.63-2.90	0.49
	Female	1.00		
Age	Per 1 increase	0.99	0.96-1.02	0.42
Histology	NSCLC	0.41	0.20-0.81	0.011
	SCLC	1.00		
EGFR status	Mutant	0.97	0.37-2.19	0.95
	Unknown	0.63	0.24-1.84	0.38
	Wild type	1.00		
PPI	>6	4.06	2.35-6.92	<0.0001
	≤6	1.00		

EGFR, epidermal growth factor receptor; PPI, Palliative Prognostic Index